Prothena Corp Public Ltd Co SEC filings PRTA
Prothena Corp Public Ltd Co has 1,006 filings in SEC EDGAR's recent list, going back to Jan 31, 2013. Its latest annual report, Form ARS, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Mar 27, 2026 | — |
| DEF 14A | Proxy statement | Mar 27, 2026 | May 14, 2026 |
| DEFA14A | Additional proxy material | Nov 6, 2025 | — |
| DEFA14A | Additional proxy material | Oct 7, 2025 | — |
| DEF 14A | Proxy statement | Oct 7, 2025 | Nov 19, 2025 |
| PRE 14A | Preliminary proxy statement | Sep 25, 2025 | Nov 19, 2025 |
| DEFA14A | Additional proxy material | Mar 28, 2025 | — |
| DEF 14A | Proxy statement | Mar 28, 2025 | May 13, 2025 |
| DEFA14A | Additional proxy material | Mar 29, 2024 | — |
| DEF 14A | Proxy statement | Mar 29, 2024 | May 14, 2024 |
| DEFA14A | Additional proxy material | Mar 31, 2023 | — |
| DEF 14A | Proxy statement | Mar 31, 2023 | — |
| DEFA14A | Additional proxy material | May 5, 2022 | — |
| DEFA14A | Additional proxy material | Apr 25, 2022 | — |
| DEFA14A | Additional proxy material | Mar 31, 2022 | — |
| DEF 14A | Proxy statement | Mar 31, 2022 | May 17, 2022 |
| PRE 14A | Preliminary proxy statement | Mar 11, 2022 | May 17, 2022 |
| DEFA14A | Additional proxy material | Mar 31, 2021 | — |
| DEF 14A | Proxy statement | Mar 31, 2021 | May 18, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 15, 2021 | May 18, 2021 |
| DEFA14A | Additional proxy material | Apr 24, 2020 | — |
| DEFA14A | Additional proxy material | Mar 25, 2020 | — |
| DEF 14A | Proxy statement | Mar 25, 2020 | May 19, 2020 |
| PRE 14A | Preliminary proxy statement | Mar 12, 2020 | May 19, 2020 |
| DEFA14A | Additional proxy material | Mar 28, 2019 | — |
| DEF 14A | Proxy statement | Mar 28, 2019 | May 21, 2019 |
| DEFA14A | Additional proxy material | Mar 29, 2018 | — |
| DEF 14A | Proxy statement | Mar 29, 2018 | May 15, 2018 |
| DEFA14A | Additional proxy material | May 8, 2017 | — |
| DEFA14A | Additional proxy material | Apr 10, 2017 | — |
| DEFA14A | Additional proxy material | Mar 31, 2017 | — |
| DEF 14A | Proxy statement | Mar 31, 2017 | May 17, 2017 |
| PRE 14A | Preliminary proxy statement | Mar 6, 2017 | May 17, 2017 |
| DEFA14A | Additional proxy material | Apr 4, 2016 | — |
| DEF 14A | Proxy statement | Apr 4, 2016 | May 19, 2016 |
| PRE 14A | Preliminary proxy statement | Mar 10, 2016 | May 19, 2016 |
| DEFA14A | Additional proxy material | Apr 2, 2015 | — |
| DEF 14A | Proxy statement | Apr 2, 2015 | May 21, 2015 |
| DEFA14A | Additional proxy material | Mar 31, 2014 | — |
| DEFA14A | Additional proxy material | Mar 31, 2014 | — |
| DEFA14A | Additional proxy material | Mar 31, 2014 | — |
| DEFA14A | Additional proxy material | Mar 31, 2014 | — |
| DEF 14A | Proxy statement | Mar 31, 2014 | May 21, 2014 |
| DEFA14A | Additional proxy material | Apr 30, 2013 | — |
| DEFA14A | Additional proxy material | Apr 10, 2013 | — |
| DEFA14A | Additional proxy material | Apr 10, 2013 | — |
| DEF 14A | Proxy statement | Apr 10, 2013 | May 22, 2013 |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PRTA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ireland
- Headquarters
- Dublin 2, Ireland
- SEC filer status
- Accelerated filer
- SEC CIK
- 1559053
- Former names
- Prothena Corp plc (until May 22, 2020); Neotope Corp Ltd (until Oct 1, 2012)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.